OGNNYSEPharmaceutical PreparationsFiscal year ends December 31
Organon & Co.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$13.75−0.01 (-0.07%)
Close on Oct 19, 2026
- Market cap
- $3.72B
- P/E (TTM)
- 17.6
- Dividend yield
- 2.47%
Share price
+$4.47 (+48.17%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
Organon & Co. saw revenue fall 2.5% to $6.13B over the twelve months to Jun 30, 2026. Free cash flow was $567.00M, down 13.8% from a year earlier.
Revenue
$6.13B
-2.5% vs. a year earlier
Free cash flow
$567.00M
-13.8% vs. a year earlier
EPS, diluted
$0.78
-71.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.72B
- P/E ratio
- 17.6
- Price to sales
- 0.61
- Price to book
- 3.70
- Dividend yield
- 2.47%
- Free cash flow yield
- 15.25%
Fundamentals
- Revenue
- $6.13B
- Net income
- $209.00M
- EPS, diluted
- $0.78
- Free cash flow
- $567.00M
- Book value per share
- $3.72
- Diluted shares
- 270M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$6.13B-2.5% YoY
Gross profit
$3.23B-8.7% YoY
Net income
$209.00M-70.1% YoY
EPS, diluted
$0.78-71.0% YoY
Free cash flow
$567.00M-13.8% YoY
Reported periodTrailing twelve months